How Foundayo Oral Pill Works: The Science Behind the Once-Daily GLP-1 Tablet

• Why most GLP-1 medicines have to be injected, and how Foundayo gets around it
• Verified facts on how the tablet is absorbed, how long it lasts and why food does not matter
• How Foundayo differs from oral semaglutide tablets
• Online consultation with UK-registered prescribers to see if an oral option suits you

For years, many GLP-1 medicines used for weight management have been given by injection. One reason is that medicines such as semaglutide and tirzepatide are peptide-based molecules that are not readily absorbed when swallowed. Foundayo (orforglipron) takes a different approach: it is a small, non-peptide molecule that activates the GLP-1 receptor and can be taken as a once-daily tablet. 

This guide explains why oral GLP-1 delivery has been challenging, how orforglipron is absorbed, what this means for taking Foundayo, and how it differs from oral semaglutide.

Key things to know

• Foundayo's active ingredient, orforglipron, is a small, chemically made molecule rather than a peptide, so digestive enzymes do not break it down
• Orforglipron has high oral bioavailability for a small-molecule GLP-1 medicine; in a phase 1 study, mean absolute oral bioavailability was about 79%. Oral semaglutide has much lower bioavailability, estimated at about 1–2%.
• It lasts 29 to 49 hours in the body, which allows once-daily dosing and reaches steady levels after about a week
• Food lowers absorption only slightly, so Foundayo can be taken at any time, with or without food
• The UK leaflet says to swallow the tablet whole and not to break, crush or chew it
• Oral semaglutide tablets need an absorption enhancer and must be taken on an empty stomach; Foundayo does not

Why Most GLP-1 Medicines Are Injections

GLP-1 is a natural hormone made in the gut. It is a peptide, a short chain of amino acids. Medicines such as Mounjaro (tirzepatide) and Wegovy (semaglutide) are also peptides, engineered to last much longer than the natural hormone. Two problems stop peptides working well as tablets.

Barrier one: digestion

The stomach and small intestine are designed to break down proteins and peptides from food. Stomach acid and enzymes such as pepsin, then further enzymes in the small intestine, cut peptide chains into individual amino acids. Peptide medicines taken by mouth can be broken down by digestive processes and generally cross the intestinal lining poorly, making it difficult to achieve adequate systemic exposure.

Barrier two: absorption

Even a peptide that survives digestion struggles to get into the bloodstream. Peptides are large and carry electrical charges, so they pass poorly through the cells lining the gut wall. Most of a swallowed dose simply never reaches the circulation.

These two barriers are why injections have been the standard. Injecting under the skin bypasses the gut entirely and delivers the medicine straight into tissue from which it is absorbed into the blood.

How Orforglipron Gets Around Both Barriers

A small molecule, not a peptide

Orforglipron was discovered by Chugai Pharmaceutical and developed by Eli Lilly. It is chemically synthesised rather than built from amino acids, which helps it remain stable in the harsh stomach environment. Because orforglipron is a non-peptide small molecule, it is not subject to the same proteolytic breakdown that limits the oral absorption of peptide medicines.

Designed to be absorbed

In a phase 1 study, the mean absolute oral bioavailability of orforglipron was about 79%. The UK product information reports high oral bioavailability and confirms equivalent exposure between the studied capsule formulation and the corresponding film-coated tablet strengths.

Activating the receptor from a different site

Orforglipron activates the same GLP-1 receptor targeted by peptide GLP-1 medicines, but it binds to a different part of the receptor. Laboratory studies have identified distinctive signalling properties, including partial and biased agonism. These findings are scientifically interesting, but they do not by themselves show that the medicine produces better clinical outcomes in people. Its clinical benefits and risks are established through human trials.

What Happens After You Swallow the Tablet

The following figures come from Lilly's published pharmacology data for orforglipron.

Why food does not matter

Food can change orforglipron exposure somewhat, but the effect has not been considered clinically relevant. In the UK product information, Foundayo can therefore be taken once daily at any time of day, with or without food.

Why once a day is enough

A half-life of 29 to 49 hours means the level in your blood falls slowly between doses. Taking one tablet every day keeps it at a steady level, reached after about a week. Foundayo is a once daily tablet. This long half-life is also why a missed dose is simply taken when you remember, as long as you never take two in one day, as part of its flexible dosing regimen.

What Happens in Your Body Once It Is Absorbed

Once absorbed, orforglipron activates GLP-1 receptors involved in appetite and glucose regulation. It increases glucose-dependent insulin secretion and reduces food intake, with reduced appetite thought to contribute to its effect on body weight. It also delays gastric emptying, although this effect is greatest after the first dose and diminishes over time. Animal studies have shown distribution to and activation of appetite-related brain regions, but the clinical effects in humans are established through human trials.

Foundayo Compared With Oral Semaglutide

Foundayo is not the first GLP-1 tablet. Oral semaglutide has been available for type 2 diabetes for several years, and a higher-dose semaglutide tablet for weight management was approved in the UK in 2026, sometimes referred to as the wegovy pill. The two approaches are fundamentally different.

Oral semaglutide is still a peptide. To get it absorbed, it is combined with an absorption enhancer called SNAC, which briefly protects the peptide in the stomach and helps it cross the stomach lining. Even so, only a very small fraction of each dose, well under 1%, reaches the bloodstream. Food and large amounts of drink interfere with this process, so oral semaglutide has to be taken on an empty stomach with only a small sip of water, followed by a wait before eating, drinking or taking other medicines.

In clinical trials, orforglipron produced substantial weight loss. In ATTAIN-1, the highest studied dose produced an average 12.4% reduction in body weight at 72 weeks.

Oral semaglutide has also produced substantial weight loss in clinical trials. In the OASIS 4 trial reported in the UK product information, the 25 mg Wegovy tablet produced a mean 13.6% reduction in body weight at week 64.

These figures come from different trials with different populations, treatment regimens and study designs, so they should not be interpreted as a direct head-to-head comparison. The same caution applies when comparing oral medicines with injectable treatments such as tirzepatide.

How to Take the Foundayo Tablet

The UK patient leaflet gives clear instructions:

• Foundayo is a once daily oral tablet, taken at any time of day
• Take it with or without food
• Swallow the tablet whole; do not break, crush or chew it
• Never take more than one tablet a day
• If you miss a dose, take it as soon as you remember, but do not take two doses in one day
• Store the tablets in their original package to protect them from light, as the medicine is light sensitive

There are no food or water restrictions when taking it.Foundayo starts at a starting dose of 0.8 mg once daily for 30 days, then increases to 2.5 mg. Further increases to 5.5 mg, 9 mg, 14.5 mg and the maximum dose of 17.2 mg happen only if needed, with at least 30 days at each step. Each strength is a different tablet, so a low dose always means a different tablet, never part of a larger one.This allows the prescriber to see how your body responds before each dose increases.

A Tablet Does Not Mean Fewer Side Effects

It is natural to wonder whether a tablet might be gentler than an injection, but the route of administration does not remove the effects caused by GLP-1 receptor activation. Foundayo's most common side effects are gastrointestinal, including nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain. In the placebo-controlled phase 3 weight-management studies, gastrointestinal disorders occurred in 60.1%, 67.4% and 68.7% of participants receiving the three studied orforglipron doses, compared with 36.3% receiving placebo. These gastrointestinal reactions were mostly mild or moderate and were more common during dose escalation.

In ATTAIN-1, treatment discontinuation because of adverse events occurred in 5.3% to 10.3% of participants receiving orforglipron, compared with 2.7% receiving placebo.

Serious adverse reactions reported in the UK product information include acute pancreatitis and serious allergic reactions. Kidney problems have also been reported, sometimes requiring dialysis, particularly in the context of dehydration from vomiting or diarrhoea.

Using Foundayo With Other Medicines

Foundayo can also affect some other medicines. For example, it can increase exposure to rosuvastatin and the active form of simvastatin, so the prescriber may need to adjust treatment. The UK leaflet names examples including clarithromycin, itraconazole, ketoconazole, ritonavir, carbamazepine, rifampicin, phenytoin and St John's wort. Foundayo can also raise levels of simvastatin and rosuvastatin. Before starting treatment, discuss your medical history and full medical history with your prescriber so they can assess whether it is suitable for you.

It may also make the contraceptive pill less effective. The leaflet advises using a barrier method as well, or switching to a non-oral method, for 30 days after starting and for 30 days after each dose increase. If you take insulin or a sulfonylurea for diabetes medicines, your prescriber may need to lower their dose to avoid low blood sugar. Patients should consult their healthcare providers regarding personal medical history before use.

Common Myths About the Foundayo Pill

"It is just a tablet version of Mounjaro or Wegovy"

It is not. Foundayo contains a different active ingredient, orforglipron, which is a different type of molecule from tirzepatide or semaglutide. It acts on the GLP-1 receptor, like semaglutide, but it is a separate medicine with its own trials and its own licence. Foundayo is one of several weight loss treatments and should not be treated as identical to alternative weight loss treatments.

"Like other GLP-1 tablets, it has to be taken on an empty stomach"

That rule applies to oral semaglutide, because its absorption depends on an empty stomach. Foundayo is absorbed well with or without food, so there is no fasting or waiting rule, giving it a more flexible dosing regimen than oral semaglutide.

"I can split a tablet to take a smaller dose"

The UK leaflet says to swallow the tablet whole and not to break, crush or chew it. Each strength is its own tablet, and dose changes should only be made by your prescriber.

"Because it is a pill, it is milder or safer"

The fact that Foundayo is a tablet does not mean it has fewer or milder adverse effects. Its UK product information includes important warnings and precautions, and gastrointestinal effects are common.

Who Foundayo Is Licensed For in the UK

Foundayo was authorised by the UK , MHRA (Medicines and Healthcare products Regulatory Agency), on 10 August 2026. It is licensed for weight management, alongside a reduced-calorie diet and more physical activity, in adults with a body mass index (BMI) of 30 or more, or 27 to under 30 with at least one weight related health condition. Eligible users must be aged 18 or over, and Foundayo is not suitable for individuals under 18 years old.

Examples of weight related health problems include high blood pressure and obstructive sleep apnoea. It is also licensed for adults with type 2 diabetes whose blood sugar is not adequately controlled. The same tablet and the same pharmacology apply to both uses.

Is an Oral GLP-1 Right for You?

An oral option may appeal to people who prefer tablets or want to avoid injections. Injectable GLP-1-based medicines may appeal to people who prefer less frequent dosing. The most appropriate option depends on the medicine's approved indication, expected benefits, risks, other medicines and your individual health history.